Cidara Therapeutics, Inc. announced the appointment of Christopher Kurtz as executive vice president of technical operations. Mr. Kurtz brings more than 26 years of experience in global manufacturing, engineering, supply chain, CMC development and program management for drugs and devices at various stages of development. Prior to joining Cidara, Mr. Kurtz served as head of commercial API manufacturing at Gilead Sciences, where he and his team played an instrumental role in the recent launches of products such as Biktarvy and Veklury. He previously served as vice president, for drug device industrialization at AbbVie, where he led product scale-up and industrialization projects for drug-device combinations.